AstraZeneca PLC EBIT

The latest EBIT for AZN.ST is $14B as of June 2026. That compares with $12B in the prior-year period — up 21.8% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside AstraZeneca PLC's historical trend and sector peers before judging valuation or financial health.

Over the past year, AZN.ST's EBIT moved from $12B to $14B — a 21.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AstraZeneca PLC's operating scale or balance-sheet position.

Against Healthcare companies, AZN.ST currently prints $14B for EBIT, while the sector average sits near $110B. That is roughly 86.7% below the sector mean. Large gaps often invite a closer look at AstraZeneca PLC's growth, margins, and balance sheet.

A EBIT figure of $14B for AZN.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting AZN.ST's EBIT ($14B), review year-over-year change from $12B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.